5 Key Takeaways

• 1

  The FDA approved tavapadon (Juvmo) for treating adults with Parkinson disease, as announced by AbbVie.

• 2

  The approval was based on the phase 3 TEMPO clinical trial program evaluating tavapadon in early Parkinson disease.

• 3

  In TEMPO-1, tavapadon improved daily living activities at week 26 compared to placebo, with significant score reductions.

• 4

  TEMPO-3 showed that tavapadon increased daily 'on' time without troublesome dyskinesia compared to placebo.

• 5

  Common mild to moderate adverse events included nausea, dizziness, and headache, with specific events varying by treatment.